Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy.

This article discusses a case of delayed onset eruptive keratoacanthomas in a 77-year-old male patient who had received pembrolizumab treatment for non-small-cell lung cancer. The patient developed a painful and pruritic eruption on his left upper extremity five months after completing a two-year course of pembrolizumab. The lesions were successfully managed with topical and intralesional corticosteroids. The article highlights the importance of continued clinical monitoring following drug cessation and offers conservative management strategies for pembrolizumab-induced eruptive keratoacanthomas. [Extracted from the article]